CY1119779T1 - Πεγκυλiωmenh l-ασπαραγιναση - Google Patents

Πεγκυλiωmenh l-ασπαραγιναση

Info

Publication number
CY1119779T1
CY1119779T1 CY20171100834T CY171100834T CY1119779T1 CY 1119779 T1 CY1119779 T1 CY 1119779T1 CY 20171100834 T CY20171100834 T CY 20171100834T CY 171100834 T CY171100834 T CY 171100834T CY 1119779 T1 CY1119779 T1 CY 1119779T1
Authority
CY
Cyprus
Prior art keywords
conjugate
disclosed
treatment
protein
polyethylene glycol
Prior art date
Application number
CY20171100834T
Other languages
English (en)
Inventor
Thierry Abribat
Original Assignee
Jazz Pharmaceuticals II S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42670528&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119779(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2010/054156 external-priority patent/WO2011003633A1/en
Application filed by Jazz Pharmaceuticals II S.A.S. filed Critical Jazz Pharmaceuticals II S.A.S.
Publication of CY1119779T1 publication Critical patent/CY1119779T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Αποκαλυπτόμενο είναι ένα προϊόν σύζευξης μιας πρωτεΐνης που έχει ουσιαστική δραστικότητα αμινοϋδρολάσης L-ασπαραγίνης και πολυαιθυλένο γλυκόλης. Ιδιαιτέρως η πολυαιθυλένο γλυκόλη έχει μοριακό βάρος μικρότερο από ή ισοδύναμο προς περίπου 5000 Da και η πρωτεΐνη είναι L-ασπαραγινάση από Erwinia. Το προϊόν σύζευξης της εφεύρεσης έχει δείξει ανώτερες ιδιότητες όπως διατήρηση ενός υψηλού επιπέδου in vitro δραστικότητας και μη αναμενόμενη αύξηση στην ημίσεια-ζωή in vivo. Επίσης αποκαλυπτόμενες είναι μέθοδοι παραγωγής του προϊόντος σύζευξης και χρήση του προϊόντος σύζευξης στη θεραπεία. Ιδιαιτέρως, αποκαλύπτεται μία μέθοδος για χρήση του προϊόντος σύζευξης στη θεραπεία καρκίνου, ιδιαιτέρως Οξείας Λεμφοβλαστικής Λευχαιμίας (ALL). Πιο ειδικά, αποκαλύπτεται μία μέθοδος για χρήση του προϊόντος σύζευξης ως δεύτερης σειράς θεραπεία για ασθενείς οι οποίοι έχουν αναπτύξει υπερευαισθησία ή είχαν υποτροπή ασθένειας μετά από θεραπεία με άλλα παρασκευάσματα L-ασπαραγινάσης.
CY20171100834T 2009-07-06 2017-08-03 Πεγκυλiωmenh l-ασπαραγιναση CY1119779T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22332009P 2009-07-06 2009-07-06
PCT/EP2010/054156 WO2011003633A1 (en) 2009-07-06 2010-03-30 Pegylated l-asparaginase
PCT/EP2010/059599 WO2011003886A1 (en) 2009-07-06 2010-07-06 Pegylated l-asparaginase
EP10730170.7A EP2451486B2 (en) 2009-07-06 2010-07-06 Pegylated l-asparaginase

Publications (1)

Publication Number Publication Date
CY1119779T1 true CY1119779T1 (el) 2018-06-27

Family

ID=42670528

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100834T CY1119779T1 (el) 2009-07-06 2017-08-03 Πεγκυλiωmenh l-ασπαραγιναση

Country Status (7)

Country Link
EP (1) EP2451486B2 (el)
CY (1) CY1119779T1 (el)
HR (1) HRP20171180T4 (el)
ME (1) ME02945B (el)
PL (1) PL2451486T5 (el)
RS (1) RS57077B2 (el)
SI (1) SI2451486T2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CN110684759B (zh) * 2018-07-06 2023-10-17 南京吉芮康生物科技研究院有限公司 重组l-门冬酰胺酶及其制备方法和用途
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
GB201912020D0 (en) * 2019-08-21 2019-10-02 Porton Biopharma Ltd Therapeutic Conjugate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications

Also Published As

Publication number Publication date
ME02945B (me) 2018-04-20
HRP20171180T4 (hr) 2023-06-09
SI2451486T1 (en) 2018-01-31
PL2451486T3 (pl) 2018-02-28
HRP20171180T1 (hr) 2018-01-26
RS57077B2 (sr) 2023-06-30
RS57077B1 (sr) 2018-06-29
EP2451486A1 (en) 2012-05-16
EP2451486B2 (en) 2023-01-18
EP2451486B1 (en) 2017-05-03
SI2451486T2 (sl) 2023-05-31
PL2451486T5 (pl) 2023-05-15

Similar Documents

Publication Publication Date Title
CY1119779T1 (el) Πεγκυλiωmenh l-ασπαραγιναση
EA201270134A1 (ru) Пегилированная l-аспарагиназа
Tang et al. Reprogramming the tumor microenvironment through second‐near‐infrared‐window photothermal genome editing of PD‐L1 mediated by supramolecular gold nanorods for enhanced cancer immunotherapy
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
IL251185A0 (en) mek inhibitors and methods of using them
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
ATE523591T1 (de) Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung
AU2015276136A1 (en) Car-expressing NK-92 cells as cell therapeutic agents
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1120082T1 (el) Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
You et al. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate
ME00017B (me) Derivati kamptotecina koji imaju antitumorno dejstvo
MX2020009149A (es) Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos.
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2020013832A (es) Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
ZA202202376B (en) Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
MX2022010457A (es) Derivados de camptotecina y conjugados de esta.
CY1106617T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα συμπλοκο ψευδαργυρου-υαλουρονικου για τη θεραπεια σκληρυνσης κατα πλακας
MX2020011453A (es) Combinaciones para tratar el cancer.
EP3444351A1 (en) Ribonucleic acid aptamer having inhibitory effect on non-small cell lung cancer, and pharmaceutical composition comprising same
CY1108890T1 (el) 7-ιμινο παραγωγα καμπτοθεκινης που εχουν αντιογκικη δραση